Andrew Huberman's Favorite Peptide: Sermorelin

Summary

In the latest episode by Peptide Buddy, the focus is on Andrew Huberman's favorite peptide, Sermorelin. Originally discussed on the Flagrant 2 podcast, this peptide is a 29 amino acid derivative of Growth Hormone-Releasing Hormone (GHRH). It's used in diagnosing and treating growth hormone deficiencies and has shown benefits like enhanced healing in post-heart attack scenarios and possibly aiding in muscle growth and fat loss, especially in older or deficient individuals. However, research is limited and results are variable. Possible risks include injection site irritation and concerns about insulin resistance. More studies are needed to fully understand its effects.

Highlights

• Andrew Huberman discussed Sermorelin on the Flagrant 2 podcast 🎙️.
• Sermorelin, a GHRH analog, boosts growth hormone and IGF-1 📈.
• Discontinued in 2008, but not for safety reasons, merely production issues 🏭.
• Not only used for children; adults might benefit, particularly post-heart attack 💔.
• Watch out for side effects like injection site irritation and possible insulin resistance 💉.

Key Takeaways

• Andrew Huberman endorses Sermorelin, a peptide derived from GHRH 🧬.
• Sermorelin is not just for kids with growth deficiencies; it aids diagnosis too🩺.
• Was discontinued in 2008 due to manufacturing issues, not safety concerns 🔍.
• Limited yet interesting research highlights potential heart and muscle health benefits ❤️.
• Precaution advised due to possible insulin resistance and other minor concerns 🚧.

Overview

In this engaging episode, Peptide Buddy revisits Andrew Huberman's favorite peptide, Sermorelin, discussed initially on the Flagrant 2 podcast. Known for optimizing health, Huberman has highlighted Sermorelin, a 29 amino acid peptide aiding growth hormone release—a topic ripe with both intrigue and complexity.

Despite its discontinuation in 2008 due to manufacturing woes, Sermorelin's potential benefits linger in conversations. It's mainly tested for growth hormone deficiencies, showing possibilities in muscle growth and cardiac health, especially post-heart attack. Research about its full spectrum of benefits and side effects remains sparse and inconclusive.

As always, while promising, peptides and their impacts come with caveats. Limited research underscores the need for caution, particularly concerning insulin resistance and unwanted growths. The quest for optimization via peptides like Sermorelin must proceed with informed discretion as this field continues to unfold.

Chapters

• 00:00 - 00:30: Introduction and Background This chapter discusses a previous episode of 'Peptide Buddy' focusing on sermorelin, which is noted as a favorite topic of Andrew Huberman, a neuroscientist and speaker. The discussion references Huberman's appearance on the 'Flagrant 2' podcast with Andrew Schulz and Akash Singh, and highlights Huberman's interests in optimization strategies.
• 00:30 - 05:00: Research Summary The chapter begins with the speaker acknowledging the poor sound quality of their first video and expressing intent to revisit the topic. The speaker continues by mentioning their recent research and extending gratitude to the audience for their support through watching, liking, and subscribing. The focus is on peptides, aiming to stimulate discussion and engagement with suggestions from viewers.
• 05:00 - 10:00: Effects of Sermorelin The chapter explores the effects of Sermorelin by examining the growth hormone-releasing hormone (GHRH) pathway. It starts with the hypothalamic release of GHRH, which stimulates the anterior pituitary to release growth hormone. This, in turn, spurs the liver to release insulin-like growth factor 1 (IGF-1), which influences various functions in target tissues. Sermorelin is introduced in this context.

Andrew Huberman's Favorite Peptide: Sermorelin Transcription

• 00:00 - 00:30 hello everybody today we're going to be rehashing the thing that we talked about in the first ever episode of peptide buddy and this is Andrew huberman's favorite peptide sermorolin so he talked about it on the hilarious podcast flagrant 2 with the Andrew Schulz and Akash Singh and he's the host of the huberman lab Andrew huberman's neuroscientist really interesting speaker I like a lot of what he talks about in terms of optimization and today
• 00:30 - 01:00 we're kind of going to go through it I did some more research and since it was my first video and had terrible sound quality I figured we'd give it another go so pathway into plug so we'll start with the plug um thank you all in advance for watching this I appreciate everyone's viewing and you know suggestions comments talking about peptides in general and kind of stimulating this conversation it's awesome so the only way to support us please like And subscribe
• 01:00 - 01:30 uh so as far as the pathway goes this one we're diving back into the ghrh pathway which I'm sure we all know pretty well by now um hypothalamic release of growth hormone releasing hormone stimulates the anterior pituitary's release of growth hormone which in turn stimulates the liver's release of igf-1 and from there on it goes and stimulates many different functions within its Target tissues so samurulin also known as
• 01:30 - 02:00 ghrh-129 and grf-129 is a 29 amino acid peptide derived from growth hormone releasing hormone so if you do you know your own research on the peptide if you want to actually see articles a lot of it isn't under kind of this brand name samorolin it's under these other titles ghrh 129 grf 129 and sometimes they target the or talk about
• 02:00 - 02:30 the amino group The nh2 at the end so samorolin is one of the many ghrh receptor agonists and it's not just a treatment for children with growth hormone deficiency or it wasn't just that but it was also used as a tool to diagnose such a deficiency and kind of confirm this diagnosis so in 1997 that's when they started using sermorelin for growth hormone deficiency and you'll see a lot of the research on the topic is
• 02:30 - 03:00 kind of done back then it was discontinued in 2008 not safety concerns or anything like that but manufacturing issues out of all things all right let's get to the research so as you'll see research in the field of peptides that increase growth hormone you know the subject of many of these videos is tough to find and tough to analyze there are articles showing different outcomes and we know so little about the topic because of its breadth so for instance
• 03:00 - 03:30 the rule igf-1 is probably involved in it's a lot more vast and a lot more detailed than people can tell you at this point it's certainly more than I can tell you and these growth factors and hormones are involved in diverse biochemical operations so things big and small alike however um just getting into it IV or subcutaneously injected so Merlin does cause release of growth hormone from the
• 03:30 - 04:00 anterior pituitary you know it's a very small analog of ghrh and seems to function well so it stimulates this rise in GH igf-1 and we know that it causes these increases um from research and that it probably has effects similar to GH the caveat with GH or growth hormone is that most of the benefits seem to help people who are deficient like
• 04:00 - 04:30 children or older people the elderly so in people with deficiencies GH causes increased bone mineral density improved lean body mass so muscle growth and or replacement of fat so fat loss Sleep Quality increase with samurulin has yet to be confirmed so you know you'll see people anecdotally claiming that it helps and maybe it does it is not at all impossible that it would help it seems like it could but there's some
• 04:30 - 05:00 you know brief research we can extrapolate that's been done on you know rainbow trouts um interestingly however in both pigs and rats so Moreland has shown improved healing and Recovery in the setting of post heart attack so it's improved heart function and helps you repair the wounds inflammation and cardiac remodeling so this is kind of similar to you know you'll read that there are heart healthy
• 05:00 - 05:30 effects of growth hormone and I imagine it's similar to what we found here one study has shown small rises in prolactin luteinizing hormone and follicle stimulating hormone so I had it's uncertain next to this just because one study has shown such a teeny tiny increase and others have really shown that it's been variable and sometimes not affected just like some Studies have shown that lean body mass wasn't changed but oh with the caveat that body fat
• 05:30 - 06:00 wasn't explicitly measured so as usual with these things more research has to be done um so you know let's get to the last part risks seems to be pretty generally well tolerated of course there may be injury or irritation to the injection site I'm also at ghrh is I worry about things like growth of unwanted unwanted structures um you know as well as maybe increased
• 06:00 - 06:30 insulin resistance or worsened control of your blood sugar so possibly heading towards hyperglycemia that's what I worry about but here we go quick cut to the Chase and evidence-based episode on sermorelin thank you for watching my friends